GLP-1 RAs have been shown to significantly reduce the risk of major adverse cardiovascular events and to slow the progression of chronic kidney disease in clinical trials involving patients with T2D and/or overweight/obesity [5,6,7,84]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.